

# TREAT Asia HIV Observational Database (TAHOD)





#### Background

Therapeutics Research • Education • AIDS Training




 A cooperative network of clinicians throughout Asia and the Pacific that aims to expand capacity for the broader introduction of HIV/AIDS treatments in the region



- A multi-centre, observational study of patients with HIV
- Aims to assess HIV disease natural history in treated and untreated patients in the Asia and Pacific region.







Therapeutics Research • Education • AIDS Training



**March 2006** 



# **Site selection**

- A number of sites were involved with TREAT Asia
- Devised a site survey
  - Distributed to all sites
  - Gauged interest and ability to comply with TAHOD study methods
    - Electronic data transfer email
    - Initial 3 year commitment
    - Local ethics approval
- Aimed for broad representation across the region
- Initially 11 participating sites in the Asia and Pacific region
  - 13 from September 2004
  - 15 from September 2005



# **Patient selection**

- Patient recruitment
  - Can't hope to recruit patients that are entirely representative
    - Not a surveillance mechanism
  - Scientifically better to get good, consistent data on a limited number of patients that can be reliably followed-up
  - Target of 200 patients per site
  - Consecutive series of regularly attending patients
  - Stratified by antiretroviral treatment
    - Balances random sampling with need for good follow-up
  - Gives good data on HIV disease natural history





# TAHOD

- TAHOD population
  - Male 71%
  - Non-pediatrics, patients 18 years or older
  - Urban patients
  - Centers for excellence
  - Public funded population
- Toxicity data are collected for research purposes
- Data are collected electronically in Microsoft Excel format
  - Transferred to NCHECR
  - Compressed in Winzip format





# **Patient demographics**

Male	71%
Age (years) mean (SD)	36 (9.9)
range	18- 90 years
Exposure: MSM	18%
IDU	4%
Hetero	64%
Other/NK	14%
CD4 (cells/mm <sup>3</sup> ) mean (SD)	307 (229)
HIV (copies/ml) median (IQR)	400 (400-8,900)
Prior AIDS	41%
ARVs: HAART	77%
Mono/double	2%
None	21%



# **Toxicity data collection**

- Data specification version 1
  - Reason for treatment cessation
  - Laboratory tests
    - Haemoglobin, ALT
- Data specification version 2 (beginning March 2006)
  - Grade 3-4 clinical adverse events
    AACTG criteria
  - Additional laboratory tests
    When collected according to local site practice Therapeutics Research Education AIDS Training

TREATASIA



#### **Adverse events**

- CARDIAC
- CLINICAL HEPATITIS
- DEPRESSION/ANXIETY
- DIABETES
- DIARRHOEA
- FAT ACCUMULATION
- FATIGUE
- FRACTURE
- IMMUNE RECONSTITUTION SYNDROME (IRS)
- LACTIC ACIDOSIS (DEFINITIVE & PRESUMPTIVE)

- LIPOATROPHY
- NAUSEA/VOMITING
- PANCREATITIS
- PERIPHERAL NEUROPATHY
- RASH
- RENAL STONE
- STROKE
- OTHERS
- UNKNOWN





#### **Laboratory tests**

- Blood pressure (systolic and diastolic)
- Haemoglobin
- Cholesterol, fasting
- HDL, fasting
- Glucose, fasting
- Triglycerides, fasting

- Blood amylase,
- Blood creatinine
- Lactate
- Lipase
- Alkaline phosphatase
- ALT
- SGPT, SGOT
- Bilirubin





#### **Toxicity data collection**

- Toxicity data are to be collected prospectively for research purposes
- Data are collected in Microsoft excel format and transferred to NCHECR for central aggregation and analysis
   Every 6 months
- TAHOD Steering Committee fully support the collaboration of research into long-term monitoring of treatment related adverse events in the resource limited settings